However, some challenges still limit its implementation in clinical practice

Study confirms favourable safety profiles and encouraging efficacy of an anti-claudin 18.2 antibody-drug conjugate

Promising new data are presented for nivolumab plus ipilimumab and the single tremelimumab regular interval durvalumab regimen in Asian patients and those with impaired liver function

Early results from a phase III trial support 30-minutes infusions of immunotherapy with some advantages for patients

Promising results support the further development of new small-molecule PD-L1 inhibitors with favourable benefit–risk profiles and improved ease of use compared with antibodies

Updated data from two studies report significant improvements in recurrence-free survival and distant-metastasis free survival with pembrolizumab or nivolumab 

Several studies report on promising data with immunomodulation and alternative approaches

Final results from the KEYNOTE-522 study confirm that the integration of pembrolizumab into the treatment regimen has the potential to transform patient management, but careful patient selection and monitoring for toxicities will be crucial 

However, presented findings raise some questions about their efficacy in non-injected lesions and the durability of responses